Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 4/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | SMPD2 | O60906 | 2/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469797 | 1.00 | CHAT (0.55) | CHATCNR1SMPD2CYSLTR2CYSLTR1 | |
| SCHEMBL1469800 | 1.00 | CHAT (0.55) | CHATCNR1SMPD2CYSLTR2CYSLTR1 | |
| SCHEMBL1612562 | 0.98 | CHAT (0.57) | CHATCNR1SMPD2CYSLTR2CYSLTR1 | |
| SCHEMBL1468842 | 0.95 | CHAT (0.52) | CHATCNR1SMPD2MTNR1AMTNR1B | |
| SCHEMBL1468841 | 0.95 | CHAT (0.52) | CHATCNR1SMPD2MTNR1AMTNR1B | |
| SCHEMBL28599340 | 0.90 | CHAT (0.49) | CHATCNR1SMPD2CYSLTR2CYSLTR1 | |
| SCHEMBL1469842 | 0.88 | TLR8 (0.50) | CHATSMPD2MTNR1AMTNR1BRXRA | |
| SCHEMBL1469843 | 0.88 | TLR8 (0.50) | CHATSMPD2MTNR1AMTNR1BRXRA | |
| SCHEMBL234806 | 0.88 | CHAT (0.48) | CHATCNR1SMPD2CYSLTR2CYSLTR1 | |
| SCHEMBL1469095 | 0.86 | CHAT (0.42) | CHATCNR1SMPD2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867323-B2 | Cross-coupling reaction of organosilicon nucleophiles | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020183516-A1 | Cross-coupling reaction of organosilicon nucleophiles | UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN | 2002-12-05 | — | — | US | disclosed |
| WO-2001094355-A1 | CROSS-COUPLING REACTION OF ORGANOSILICON NUCLEOPHILES | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183516-A1 | Cross-coupling reaction of organosilicon nucleophiles | TST, HPD, PCNA | CHAT 4205/4885CNR1 3286/4885SMPD2 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.